Evidence map›Paper›PMID 42898675›Full record

ArticleBiomaterials research2026

Multi-omics Profiling Reveals the Effects of Xihuangcao on Hepatic Fibrosis Attenuation through Gut Microbiota and Metabolic Reprogramming.

Weiguo Zhao, Xueling Zhang, Lifan Xu, Mianfeng Zheng, Zhuoya Li, Yuexuan Wang, Xinxiang He, Min Hong, Huiye Zhang, Junwei Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Weiguo ZhaoDepartment of Pharmacy, Zhongshan City People's Hospital, Zhongshan 528403, China.
Xueling ZhangCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Lifan XuCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Mianfeng ZhengKey Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Zhuoya LiDepartment of Pharmacy, Zhongshan City People's Hospital, Zhongshan 528403, China.
Yuexuan WangCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Xinxiang HeDepartment of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China.
Min HongThe First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China.
Huiye ZhangHutchison Whampoa Guangzhou Baiyunshan, Chinese Medicine Company Limited, Guangzhou 510006, China.
Junwei LiHutchison Whampoa Guangzhou Baiyunshan, Chinese Medicine Company Limited, Guangzhou 510006, China.
Lei ShiCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Ying DuConsun Pharmaceutical Group Limited, Guangzhou, Guangdong 510006, China.
Haitao YuanCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Wei ZhangCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Ali ChenCenter for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In various chronic liver diseases, hepatic fibrosis represents a frequent pathological event. This process involves the activation of hepatic stellate cells, along with the consequent excessive deposition of extracellular matrix. Emerging evidence highlights the contribution of gut microbiota dysbiosis and intestinal barrier dysfunction to its progression, underscoring the potential of targeting the liver-gut axis. Xihuangcao, a traditional Chinese medicinal herb used for acute cholecystitis and jaundice hepatitis, exhibits antifibrotic activity, but its underlying mechanisms remain unclear. In this study, hepatic fibrosis models were established to evaluate the antifibrotic effects of 3 botanical sources of Xihuangcao (

Identifiers

PMID42898675
PMCPMC13678083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.